Extended-spectrum cephalosporinases in Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 5, 2009, Pages 1766-1771

  Rodríguez Martínez, José Manuel ^a   Poirel, Laurent ^a   Nordmann, Patrice ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE AMPC; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CEPHALOSPORINASE; CLOXACILLIN; ENZYME VARIANT; IMIPENEM; MEROPENEM; OXYIMINOCEPHALOSPORIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; ENZYME ANALYSIS; ENZYME KINETICS; ENZYME MECHANISM; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; SEQUENCE ANALYSIS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CEFTAZIDIME; CEPHALOSPORINASE; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PSEUDOMONAS AERUGINOSA; SEQUENCE ANALYSIS, DNA;

EID: 66149137554     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01410-08     Document Type: Article

References (31)

1. Barnaud, G., Y. Benzerara, J. Gravisse, L. Raskine, M. J. Sanson-Le Pors, R. Labia, and G. Arlet. 2004. Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate. Antimicrob. Agents Chemother. 48:1040-1042.
2. Barnaud, G., R. Labia, L. Raskine, M. J. Sanson-Le Pors, A. Philippon, and G. Arlet. 2001. Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate. FEMS Microbiol. Lett. 195:185-190.
3. Bellais, S., D. Aubert, T. Naas, and P. Nordmann. 2000. Molecular and biochemical heterogeneity of class B carbapenem-hydrolyzing β-lactamases in Chryseobacterium meningosepticum. Antimicrob. Agents Chemother. 44:1878-1886.
4. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
5. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing. 18th informational supplement. Clinical and Laboratory Standards, Wayne, PA.
6. Cornish-Bowden, A. (ed.). 1995. Fundamentals of enzyme kinetics, p. 30-37. Portland Press, London, United Kingdom.
7. Crichlow, G. V., A. P. Kuzin, M. Nukaga, K. Mayama, T. Sawai, and J. R. Knox. 1999. Structure of the extended-spectrum class C β-lactamase of Enterobacter cloacae GC1, a natural mutant with a tandem tripeptide insertion. Biochemistry 38:10256-10261.
8. Doi, Y., J. Wachino, M. Ishiguro, H. Kurokawa, K. Yamane, N. Shibata, K. Shibayama, K. Yokoyama, H. Kato, T. Yagi, and Y. Arakawa. 2004. Inhibitor-sensitive AmpC β-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins. Antimicrob. Agents Chemother. 48:2652-2658.
9. Gutiérrez, O., C. Juan, E. Cercenado, F. Navarro, E. Bouza, P. Coll, J.-L. Perez, and A. Oliver. 2007. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob. Agents Chemother. 51:4329-4335.
10. Hancock, R. E., and F. Bellido. 1996. Antibacterial in vitro activity of fourth generation cephalosporins. J. Chemother. 8(Suppl. 2):31-36. (Pubitemid 126737246)
11. Hidri, N., G. Barnaud, D. Decré, C. Cerceau, V. Lalande, J. C. Petit, R. Labia, and G. Arlet. 2005. Resistance to ceftazidime is associated with a S220Y substitution in the omega loop of the AmpC β-lactamase of a Serratia marcescens clinical isolate. J. Antimicrob. Chemother. 55:496-499.
12. Hocquet, D., P. Nordmann, F. El Garch, L. Cabanne, and P. Plésiat. 2006. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:1347-1351.
13. Hujer, K. M., N. S. Hamza, A. M. Hujer, F. Perez, M. S. Helfand, C. R. Bethel, J. M. Thomson, V. E. Anderson, M. Barlow, L. B. Rice, F. C. Tenover, and R. A. Bonomo. 2005. Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 β-lactamase: defining a unique family of class C enzymes. Antimicrob. Agents Chemother. 49:2941-2948.
14. Juan, C., M. D. Macia, O. Gutierrez, C. Vidal, J. L. Perez, and A. Oliver. 2005. Molecular mechanisms of β-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 49:4733-4738.
15. Kovach, M. E., R. W. Phillips, P. H. Elzer, R. M. Roop, and K. M. Peterson. 1994. pBBR1MCS: a broad-host-range cloning vector. BioTechniques. 16:800-802. (Pubitemid 2103380)
16. Mammeri, H., and P. Nordmann. 2007. Extended-spectrum cephalosporinases in Enterobacteriaceae. Anti-Infect. Agents Med. Chem. 6:71-82.
17. Mammeri, H., P. Nordmann, A. Berkani, and F. Eb. 2008. Contribution of extended-spectrum AmpC (ESAC) β-lactamases to carbapenem resistance in Escherichia coli. FEMS Microbiol. Lett. 282:238-240.
18. Mammeri, H., L. Poirel, P. Bemer, H. Drugeon, and P. Nordmann. 2004. Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC β-lactamase of a Serratia marcescens clinical isolate. Antimicrob. Agents Chemother. 48:716-720.
19. Mammeri, H., L. Poirel, N. Fortineau, and P. Nordmann. 2006. Naturally occurring extended-spectrum cephalosporinases in Escherichia coli. Antimicrob. Agents Chemother. 50:2573-2576.
20. Mammeri, H., L. Poirel, and P. Nordmann. 2007. Extension of the hydrolysis spectrum of AmpC β-lactamase of Escherichia coli due to amino acid insertion in the H-10 helix. J. Antimicrob. Chemother. 60:490-494.
21. Matsumura, N., S. Minami, and S. Mitsuhashi. 1998. Sequences of homologous β-lactamases from clinical isolates of Serratia marcescens with different substrate specificities. Antimicrob. Agents Chemother. 42:176-179.
22. Miller, K., A. J. O'Neill, and I. Chopra. 2002. Response of Escherichia coli hypermutators to selection pressure with antimicrobial agents from different classes. J. Antimicrob. Chemother. 49:925-934.
23. Nordmann, P., and H. Mammeri. 2007. Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol. 2:297-307.
24. Nukaga, M., S. Haruta, K. Tanimoto, K. Kogure, K. Taniguchi, M. Tamaki, and T. Sawai. 1995. Molecular evolution of a class C β-lactamase extending its substrate specificity. J. Biol. Chem. 270:5729-5735.
25. Nukaga, M., K. Taniguchi, Y. Washio, and T. Sawai. 1998. Effect of an amino acid insertion into the omega loop region of a class C β-lactamase on its substrate specificity. Biochemistry 37:10461-10468. (Pubitemid 28357569)
26. Philippon, L. N., T. Naas, A. T. Bouthors, V. Barakett, and P. Nordmann. 1997. OXA-18, a class D clavulanic acid-inhibited extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41:2188-2195.
27. Quale, J., S. Bratu, J. Gupta, and D. Landman. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50:1633-1641.
28. Raimondi, A., F. Sisto, and H. Nikaido. 2001. Mutation in Serratia marcescens AmpC β-lactamase producing high-level resistance to ceftazidime and cefpirome. Antimicrob. Agents Chemother. 45:2331-2339.
29. Vakulenko, S. B., D. Golemi, B. Geryk, M. Suvorov, J. R. Knox, S. Mobashery, and S. A. Lerner. 2002. Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 β-lactamase confers increased MIC of cefepime. Antimicrob. Agents Chemother. 46:1966-1970.
30. Walsh, T. R., M. A. Toleman, L. Poirel, and P. Nordmann. 2005. Metallo- β-lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18:306-325. (Pubitemid 40548296)
31. Weldhagen, G. F., L. Poirel, and P. Nordmann. 2003. Ambler class A extended-spectrum β-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob. Agents Chemother. 47:2385-2392.